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PPAR-gammaPeroxisome proliferator-activated receptor-gamma (PPARγ) regulates both glucose metabolism and bone mass.
Evidence suggests that the therapeutic modulation of PPARγwith synthetic agonists activity may elicit undesir-
able effects on bone. However, there is no information regarding its natural agonist 15d-PGJ2, besides its excel-
lent anti-inﬂammatory action. In the present study the effects of 15d-PGJ2 on osteoblastic cells were determined.
Osteoblastic cells (MC3T3) were cultured in an osteogenic medium in the presence of 1, 3 or 10 μM of 15d-PGJ2
during 21 days and alizarin and Von Kossa staining were employed. The protein expression (type-I collagen,
osteonectin, osteopontin, RANKL, osteoprotegerin, HDAC-9c and PPAR-γ) was evaluated after 3 days in the pres-
ence of 15d-PGJ2 by western blotting and indirect immunoﬂuorescence methods. The production of mineralized
extracellular matrix was observed by transmission electron microscopy. After 72 h of culture, the mRNA was
extracted for RT-qPCR analysis of RUNX expression. In the presence of all 3 tested 15d-PGJ2 doses, alizarin red
and Von kossa staining were positive demonstrating the ability to the osteoblast differentiation. Type-I collagen
and osteonectin proteins expression were up-regulated (p b 0.05) after 72 h in the presence of the smaller doses
of 15d-PGJ2. In contrast, osteopontin, RANKL and OPG expression did not signiﬁcantly alter. In the presence
of 15d-PGJ2 it was possible to visualize mineralized nodules in the extracellular matrix conﬁrmed with the
increased RUNX mRNA expression. 15d-PGJ2 at small doses increased the osteoblast activity and the
bone-related proteins expression.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Bone is an organ that is under constantly remodeling during the
lifetime conducted mainly by osteoblast, osteocytes and osteoclast
cells. It is known that osteoblasts and adipocytes are closely related
through a common progenitor cell [1]. Commitment of progenitor
cell toward the adipocyte or osteoblast fate occurs through a highly
regulated mechanism in which lineage-speciﬁc transcription factors
(such as Runt-related transcription factor 2 (Runx-2) for osteoblasts
and peroxisome proliferator-activated receptor-gamma (PPAR-γ)
for adipocytes).
The PPAR-γ is a nuclear receptor that controls not only
adipogenesis but also the endocrine function of adipose tissue [2].
Since thiazolidinediones (TZD), potent PPAR-γ ligands, have been
approved for clinical use in the treatment of type II diabetes iny and Molecular Biology, São
cha Junqueira, 13 Campinas/SP,
3211 3712.
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rights reserved.1999, their effects on human bone are just emerging. Clinical studies
have revealed that TZD decrease markers of bone formation with
reduction in bone mass and increase in fracture incidence [3–6].
Thus, it has been postulated that TZDs, via PPAR-γ activation, increase
adipocyte differentiation at the expense of osteoblasts in vitro [7].
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), a cyclopentenone-
type prostaglandin with a wide spectrum of physiological activities,
is one of the terminal products of the cyclooxygenase-2 (COX-2)
pathway. 15d-PGJ2 was initially discovered as an endogenous
ligand for PPAR-γ with potent anti-inﬂammatory activities [8–13].
However, studies have demonstrated that 15d-PGJ2 have also
PPAR-γ-independent effects such as inhibition of NF-kB translocation
to the nucleus through inhibition of IkBα phosphorylation [14].
Moreover, 15d-PGJ2 possess a potent suppressive effect on inﬂamma-
tory responses of osteoblast-like cells MC3T3E-1 via the Akt and
NF-κB pathways independent of PPAR-γ [15]. Besides, in a macro-
phage PPAR-γ knockout model, the lack of PPAR-γ had no effect on
the ability of PPAR-γ agonists to block pro-inﬂammatory cytokine
production [16]. Along with another studies in different models
and approaches, it is consensus that 15d-PGJ2 has a strong PPAR-γ-
independent activity.
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15d-PGJ2 might be a promising anti-inﬂammatory molecule indicated
by different approaches, and several of these effects are PPAR-γ-
independent, we delineated this experiment to understand the inﬂu-
ence of the 15d-PGJ2 in the osteoblastic phenotype.2. Material and methods
2.1. Cell culture
The mouse MC3T3-E1 pre-osteoblastic cells were obtained from
the American Type Culture Collection (Manassas, VA, USA). The
cell culture were maintained in DMEM/Ham's F-12 medium (LGC
Biotechnology, São Paulo, Brazil) supplementedwith 50 μg/mL ascorbic
acid (Sigma, St. Louis, MO, USA) and 10 mM β-glycerolphosphate
(Sigma) containing 10% fetal bovine serum and 1% antibiotics, and
cultured in a humidiﬁed atmosphere of 95% air and 5% carbon dioxide
at 37 °C. The MC3T3-E1 cells were incubated for a total period of 72 h
before all the experimental assays.2.2. Cell proliferation and cell viability assays
Cells were grown on 24 and 96 wells plates (Corning, NY, USA) in
an initial density of 110 cells/mm2 per well, respectively for the pro-
liferation and viability tests. After 72 h, the medium was changed and
supplemented or not with 15d-PGJ2 (Sigma-Aldrich, St. Louis, MO,
USA) at 1, 3 or 10 μM doses. After 24, 48, 72 or 144 h, the cells from
3 randomly wells were detached with 0.05% trypsin and counted in
Neubauer's chamber to calculate the proliferation indices. In a differ-
ent set of plates, at the same conditions described, 10 μl of MTT solu-
tion (5 mg/mL in phosphate buffer saline (PBS)) plus 90 μL of base
medium were added into each well. Cells were incubated for 3 h at
37 °C with 5% CO2, 95% air and complete humidity. After 3 h, the
MTT solution was removed and replaced with 100 μL of dimethyl
sulfoxide. The plate was further incubated for 15 min at room tem-
perature (RT), and the optical density (OD) of the wells was deter-
mined using a plate reader at a test wavelength of 590 nm in a
SpectraMax Plus microplate reader (Molecular Devices, Sunnyvale,
CA, USA). The experiments were performed at the same conditions
twice for accuracy.2.3. Alizarin red staining
In order to evaluate calcium deposits, the cells were grown on
glass coverslips (~13 mm) and analyzed after 21 days. After these
periods of treatment the cells were rinsed with Hanks' balanced salt
solution (Sigma), ﬁxed with 70% ethanol for 1 h at 4 °C, followed by
staining with 2% alizarin red S (Sigma), pH 4.2 for 15 min at RT. The
alizarin red-positive nodules were examined using light microscopy
(Nikon eclipse E800, Japan).Fig. 1. Cell growth (A) and viability assay (B) of MC3T3 cell cultures after 24, 48, 72 or
144 h of treatment with different doses of 15d-PGJ2 compared with the control group
(C). The error bars represent the standard deviations.2.4. von Kossa staining
To determine the presence of phosphate-based mineral nodules,
the cell cultures were grown on glass coverslips (~13 mm) and ana-
lyzed after 21 days. Thereafter, the cells were stained by applying
0.5% silver nitrate solution (Sigma) for 20 min under bright light
and rinsed with distilled water. Then, they were incubated with
0.5% sodium hydroquinone (Sigma) for 2 min, followed by 5% sodium
thiosulphate solution (Sigma) for 2 min. The black-stained phosphate
nodules were examined using light microscopy (Nikon eclipse E800,
Japan).2.5. Transmission electron microscopy
In order to certify the production of extracellular matrix by colla-
gen ﬁbrils formation, cells cultured on 13 mm polystyrene coverslips
(Themanox®, Thermo Scientiﬁc Nunc) were ultrastructurally ana-
lyzed after 14 days of treatment. The cells were ﬁxed in 0.1% glutaral-
dehyde and 4% formaldehyde in 0.1 mol/L sodium cacodylate buffer
(pH 7.4) for 1 hour at RT. They were rinsed in the same buffer and
post-ﬁxed in 1% osmium tetroxide for 1 h, dehydrated in a graded se-
ries of ethanol and acetone, and embedded in Spurr resin. Semi-thin
sections were cut in a Micron HM360 microtome with glass knives
made in a knife maker Leica EM KMR3 (Leica Instruments GmbH,
Nussloch, Germany) and stained with 0.25% toluidine blue. Represen-
tative areas were selected for 70-nm-thick ultrathin sections by using
a Leica Ultracut R ultramicrotome with a Diatome diamond knife
and examined with a JEM 1010 electron microscope (Jeol USA Inc,
Peabody, MA) operating at 80 kV.2.6. Immunoﬂuorescence
Cell grown on coverslips in different concentrations of 15d-PGJ2
(1, 3 or 10 μM) during 72 h, were ﬁxed in methanol for 6 min at 20
°C, rinsed in PBS followed by blocking with 1% bovine albumin in
PBS for 30 min at RT. The primary polyclonal antibodies used were
anti-type I collagen (1:50, mouse, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-osteonectin (1:50, rabbit, kindly supplied by
Fig. 2. Bone-like nodule formation. Osteoblast (MC3T3-E1) cell culture was grown in osteogenic medium alone (A, E) or with 15d-PGJ2 (1, 3 and 10 μM) (B, C, D, F, G, H) for 21 days.
Bone-like nodule formation was observed in all studied groups. Bars: A, B, C, E, F = 30 μm; D, G, H = 100 μm.
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(1:50, rabbit, Abcam, Cambridge, UK). Control staining reaction
was performed using PBS in substitution to the primary antibody.
The secondary antibody used was biotinylated anti-rabbit IgG or
anti-mouse IgG (Vector Laboratories Inc, Burlingame, CA, USA). Follow-
ing, ﬂuorescein-streptavidin conjugated (Vector) was used. After wash-
ing, preparations were mounted using Vectashield DAPI-associated
(4'-6-diamidino-2-phenylindole) (Vector) and observed on a Zeiss
Axioskop 2 conventional ﬂuorescence microscope (Carl Zeiss
MicroImaging GmbH, Germany) equippedwith 63x Plan Apochromatic
1.4NA and 100x Plan Apochromatic 1.4NA objectives in standard condi-
tions (Carl Zeiss, Oberköchen, Germany). The immunoﬂuorescence
experiments were repeated three times for each 15d-PGJ2 concentra-
tion tested.
2.7. Real time quantitative PCR
Cells were grown during 72 h in the presence or not of 15d-PGJ2
(1, 3 or 10 μM) for the evaluation of the mRNA levels of Runt-relatedFig. 3. Transmission electron micrographs of MC3T3 cell cultures. In the control group (C), f
presence of 15d-PGJ2. Col: Collagen; MN: Mineralizing Nodules; Bars: A = 500 nm; B = 25transcription factor (RUNX) and Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). Total RNA was isolated by the Trizol method
(Gibco BRL, Life Technologies, Rockville, MD, USA) according to the
manufacturer's recommendation. RNA samples were re-suspended
in diethylpyrocarbonate-treated water and stored at−70 °C. The RNA
concentration was determined from the OD using a micro-volume
spectrophotometer (Nanodrop 1000, Nanodrop Technologies LLC,
Wilmington, NC, USA). Reverse transcription total RNA was DNase
treated (Turbo DNA-frees, Ambion Inc., Austin, TX, USA), and 1 μg was
used for cDNA synthesis. The reaction was carried out using the
First-Strand cDNA synthesis kit (Fermentas, Glen Burnie, MD, USA),
following the manufacturer's recommendations. Primers were
designed using the Primer Express 3.0 probe design software (Applied
Biosystem, Foster City, CA, USA). Quantitative real-time polymerase
chain reaction (qPCR) was performed in the 7300 Real Time PCR (Ap-
plied Biosystem) using the SYBR Green PCR Master Mix (Fermentas).
The reaction product was quantiﬁed with the Relative Quantiﬁcation
tool, using GAPDH as the reference gene. Negative controls with SYBR
Green PCR Master Mix and water were performed for all reactions.ew collagen ﬁbrils and some minerals appeared. The same pattern was observed in the
0 nm.
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Cells were grown during 72 h in the presence or not of 15d-PGJ2
(1, 3 or 10 μM) then the cell lysates were prepared by homogeniza-
tion at 4 °C and centrifuged at 15.000 g for 15 min at 4 °C. The protein
concentration was measured by BCA assay (Pierce, Rockford, IL, USA).
Protein extracts were separated in a 10% sodium dodecylsulfate–
polyacrylamide gels, transferred onto polyvinylidene diﬂuoride
membranes (Hybond; Amersham Biosciences, Piscataway, NJ, USA),
and probed for 1 hour with the primary antibodies anti-collagen-I,
anti-osteopontin, anti-osteonectin, anti-Receptor activator of nuclear fac-
tor kappa-B ligand (RANKL), anti-osteoprotegerin (OPG), anti-PPAR-γ
and anti-Histone deacetylase 9c (HDAC-9c) (1:1000) diluted in TBST +
5% of low fat milk. The α-tubulin primary antibody was used as an
endogenous control (1:1000; Santa Cruz Biotechnology, Santa Cruz,
CA). After incubationwith amouse or rabbit monoclonal secondary anti-
body (1:2500), the reaction was revealed with Bio-Rad Laboratories
(Hercules, CA, USA) Western blotting chemiluminescent detection
reagents (Opti-4CN) into x-ray ﬁlms (GE Healthcare, Fairﬁeld, CT, USA).
OD measurements were made with NIH Image 1.37 (National InstitutesFig. 4. Immunostaining for type I collagen (Col I), osteopontin (OPN) and osteonectin (ONEC).
deposits throughout the cytoplasm inmineralizingmedium alone (A, B, C) or in the presence of
in blue. Bar = 20 μm.of Health, Bethesda, MD) for scanned membranes. All experiments
were made in duplicate in 3 different sets. Fold induction was calculated
by normalizing relative OD values to that of the control value that was
taken as 1.
3. Statistical analysis
To determine if there were signiﬁcant differences the data was
analyzed using the one-way ANOVA or two-way ANOVA. If there was
a signiﬁcant among-subjects main effect of treatment group following
one-way ANOVA, post-hoc using the Tukey test, were performed to
determine the basis of the signiﬁcant difference (one-way ANOVA) or
Bonferroni (two-way ANOVA). The signiﬁcance level considered was
lower than 5%.
4. Results
In order to verify the cytotoxicity of the 15d-PGJ2 in MC3T3 cell
culture, we have performed proliferation and viability cell assays in
different periods and doses. Thus, stimulation by 15d-PGJ2 with all 3Col I (A, D, G, J), OPN (B, E, H, K) and ONEC (C, F, I, L) was immune-expressed as punctuate
15d-PGJ2 at 1 μM(D, E, F), 3 μM(G, H, I) and 10 μM(J, K, L). Nuclei stainedwithDAPI appear
Fig. 5. Effects of 15d-PGJ2 on bone markers expression on MC3T3-E1 cells. Type-I Collagen (A), osteonectin (B), osteopontin (C) and α-tubulin protein expression of osteoblast cells
in the presence or not of 15d-PGJ2 (1, 3 or 10 μM) was analyzed by Western blotting. Data are representative of 3 independent experiments in duplicate. Different letters indicates
statistical signiﬁcance (one way ANOVA followed by Bonferroni test).
Fig. 6. Real Time qPCR expression. Effects of the 15d-PGJ2-treated osteoblast cells
on RUNX mRNA relative expression at 72 h on culture using real-time PCR. The
results are presented as the expression of the target mRNA normalized by GAPDH.
The values are representative of 3 independent experiments in duplicate (mean ± SD).
The symbol * indicates statistical signiﬁcance in comparison to control group (two way
ANOVA followed by Bonferroni test).
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nor the cell viability (Fig. 1B).
Next, the in vitromineralization of the extracellular matrix protein
evaluated by alizarin red (Fig. 2A, B, C, D) and von kossa (Fig. 2 E, F, G,
H) staining supported the cell proliferation and viability experiments.
When the cells were treated with different doses of 15d-PGJ2,
bone-like nodules formation was identiﬁed in all studied conditions,
as well as in the positive control group treated with mineralizing
factors alone. Ultrastructural examination of MC3T3 cell cultures treat-
ed or not with 15d-PGJ2 conﬁrmed the presence of few collagen ﬁbrils
and among them some calciﬁcation nodules, corroborating the pres-
ence of mineralizing nodules was also observed in all studied doses of
15d-PGJ2 (Fig. 3).
The immunoﬂuorescence expression of type I collagen (Col I),
osteopontin (OPN) and osteonectin (ONEC) was detected throughout
punctuate deposits throughout the cytoplasm, mainly in the perinuclear
region that corresponds to the Golgi apparatus in the presence as well
in the absence of 15d-PGJ2 (Fig. 4). This proteins expression was also
semi quantitatively analyzed by Western blotting. Interesting, only the
lowest doses of 15d-PGJ2 (1 μM) induced statistical signiﬁcant increase
(p b 0.05) on type I collagen expression (Fig. 5A). In addition, doses of 1
and 3 μM of 15d-PGJ2 statistically increased (p b 0.05) the expression
of osteonectin (Fig. 5B). On the other hand, the presence of different
doses of 15d-PGJ2 induced only a slight increase in the osteopontin
levels but not statistically signiﬁcant (Fig. 5C, p > 0.05). Also, as demon-
strated in Fig. 6, the RUNX mRNA was up-regulated in the presence of
15d-PGJ2, although only the dose of 3 μM showed statistical difference
(p b 0.05).
Since the osteoblastic cells are an important source of bone
metabolic molecules, such as RANKL and OPG, the expression of these
proteins was evaluated in these cells under 15d-PGJ2 supplementation.Interestingly, after 72 h in the presence of 15d-PGJ2, it was observed
a tendency to decrease the RANKL expression, mainly at the lower
doses, by osteoblast cells, although no statistical signiﬁcance was
detected (Fig. 7A). On the other hand, the OPG expression had slightly
increased in the presence of 15d-PGJ2 but not statistically signiﬁcant
(Fig. 7B).
As observed in Fig. 8, neither the cytosolic PPAR-γ (A) nor nuclear
PPAR-γ (B) expression was signiﬁcantly increased in the presence of
different doses of 15d-PGJ2. On the other hand, the HDAC-9c has
Fig. 7. Effects of 15d-PGJ2 on RANKL and OPG expression on MC3T3-E1 cells. Osteoblast cells were cultured in the presence or not of 15d-PGJ2 (1, 3 or 10 μM) and the protein
expression was analyzed by Western blotting. The proteins were collected after 3 days on culture. The intensity of optical density of the bands was normalized by α-tubulin
expression. Data are representative of 3 independent experiments in duplicate. Different letters indicates statistical signiﬁcance (one way ANOVA followed by Bonferroni test).
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parison to control (Fig. 8C).
5. Discussion
It is consensus that PPAR-γ plays an important role in skeletal me-
tabolism. Speciﬁcally, PPAR-γ haplo-deﬁcient mice exhibit increased
bone mass associated with increased osteoblastogenesis and decreased
adipogenesis [17]. Therefore, increased PPAR-γ activation may contrib-
ute to the reduced osteoblast production and bone loss that occurs with
aging [18]. On the other hand, the 15d-PGJ2 that is an endogenous mol-
ecule that may bind to PPAR-γ, is generated in response to tissue injury
[19,20] during the resolution phase of inﬂammation [21], and has been
demonstrated as an excellent anti-inﬂammatory drug when exoge-
nously administrated [10,12,22,23]. In the present study it was demon-
strated that low doses of 15d-PGJ2 improve the osteoblast activity in
a PPAR-γ-independent manner due to, at least in part, to the elevated
expression of Histone Deacetylase 9c (HDAC-9c).
Using murine marrow-derived mesenchymal cells, as well as
a model marrow-derived stromal cell line over-expressing PPAR-γ2,
it was shown that activation of PPAR-γ2 with rosiglitazone and,
in a lesser extent 15d-PGJ2, stimulates adipogenesis and inhibits
osteoblastogenesis in U33/γ2 cells [7]. Compared with rosiglitazone,
the degree of maximal adipogenesis stimulation achieved by 15dPGJ2,
9-HODE, and 9,10-DHOA was signiﬁcantly lower [7].
MC3T3-E1 cell line, derived from newborn mouse calvaria, is
considered a good model for studying osteoblasts differentiation,
particularly extracellular matrix signaling after growth in ascorbic
acid and inorganic phosphate medium [24]. Our results are consistent
with the literature, which demonstrated collagen ﬁbrils formation
followed by nodules matrix formation [25]. As a pre-requisite of the
onset of mineralization, osteopontin and osteonectin were detected
indicating maturation of the osteoblasts [26]. Therefore, the presenceof lower doses of 15d-PGJ2 clearly favored osteoblast cells to produce
osteonectin and type I collagen, as well as to deposit mineral nodules.
After the early stages of cell culture, osteoblasts synthesize the extra-
cellular matrix, followed by activation of bone differentiation markers
in awell-known temporal sequence [27]. Considering this, type I collagen
is essential for induction of osteoblasts differentiation markers, such as
bone sialoprotein protein, osteonectin and osteopontin [28–30]. Thus,
our results have demonstrated that 15d-PGJ2 supplementation did not
affect osteoblasts differentiation, and also lower doses of 15d-PGJ2 con-
tributed for increased bone-related proteins expression.
15d-PGJ2 is generated as a consequence of dehydration of PGD2, a
principal COX-2 product formed in various cells and tissues during the
inﬂammatory processes [31]. PGD2 is spontaneously converted into pros-
taglandin J2 (PGJ2), which undergoes intramolecular rearrangement
of the 13,14-double bond followed by dehydration to form 15d-PGJ2
[32]. The electrophilic α,β-unsaturated carbonyl group present in its
cyclopentenone ring allow the interaction with critical cellular nucleo-
philes. Several of the biological effects elicited by 15d-PGJ2 aremediated
by modulating the activities of some key transcription factors, such as
nuclear factor-kappaB (NF-kB), signal transducers and activators of
transcription 3 (STAT3), nuclear factor-erythroid 2p45 (NF-E2)-related
factor (Nrf2), activator protein-1 (AP-1), hypoxia inducible factor,
p53, thioredoxin [33]. Moreover, the modulation of the transcription
factors and other signaling molecules by 15d-PGJ2 is not necessarily
mediated via PPAR-γ activation [32]. Our data has also demonstrated
that among the low doses used, the PPAR-γ expression was not
up-regulated in contrast to HDAC-9c. This is an important observation
that may explain the absence of increased PPAR-γ levels under the
inﬂuence of 15d-PGJ2.
The acetylation of histone proteins, loosens the structure of the
target gene promoter and results in increased accessibility for tran-
scription factors and RNA polymerase II, thus initiating transcription.
Conversely, deacetylation of histone proteins mediated by histone
Fig. 8. Expression of PPAR-γ and HDAC9c. Cytosolic (c) and nuclear (n) cells extracts were harvested after 3-days culture in the presence or not of 15d-PGJ2 and western blotted
with antibodies as indicated. The intensity of optical density of the bands was normalized by α-tubulin expression. Data are representative of 3 independent experiments in
duplicate. Different letters indicates statistical signiﬁcance (one way ANOVA followed by Bonferroni test).
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and repression of transcription [34]. Several anti-inﬂammatory
drugs, as well as the immunosuppressive cytokine transforming
growth factor-β1 (TGF-β1), have been demonstrated to induce the re-
cruitment of HDACs to speciﬁc gene promoters for silencing gene ex-
pression [35,36]. It has been previously demonstrated that HDAC-9c
plays a crucial role in the acceleration of mesenchymal stem cells
(MSC) osteogenesis and attenuation of MSC adipogenesis through
interaction with PPARγ-2, which interrupts PPARγ-2 transcriptional
activity resulting in attenuation of adipogenesis and acceleration of
osteogenesis [37]. This observation may explain our results once in
the presence of low doses of 15d-PGJ2 (mainly 3 μM) we did not
observe an increased expression of the PPAR-γ in contrast to
HDAC-9c over-expression probably modulating the PPAR-γ activity.
Moreover, previous data has also demonstrated that 15d-PGJ2 inhibit
IL-1β–induced COX-2 expression by interfering with histone acetylase
p300 [38].
Altogether our results demonstrated that 15d-PGJ2 at small doses
favored the osteoblast activity and the bone-related proteins expres-
sion in a PPAR-γ-independent manner.Acknowledgments
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